Comprehensive prophylaxis and treatment of hepatitis B recurrence after liver transplantation.
- Author:
Zhong-Yang SHEN
1
Author Information
1. Organ Transplantation Center, the First Central Hospital of Tianjin, Tianjin 300192, China.
- Publication Type:Journal Article
- MeSH:
Combined Modality Therapy;
Hepatitis B Antibodies;
therapeutic use;
Hepatitis B virus;
immunology;
Hepatitis B, Chronic;
prevention & control;
Humans;
Immunoglobulins;
therapeutic use;
Lamivudine;
therapeutic use;
Liver Transplantation;
Postoperative Complications;
prevention & control;
Secondary Prevention
- From:
Acta Academiae Medicinae Sinicae
2005;27(4):431-434
- CountryChina
- Language:Chinese
-
Abstract:
The outcome of liver transplantation for end-stage liver disease secondary to hepatitis B is remarkably impacted by recurrent infection and subsequent allograft failure. Pre-operational viral replication, immunosuppression degree, and disease types play an important role in hepatitis B recurrence. This article summarizes the mechanisms, the influencing factors, and clinical diagnosis for recurrence of hepatitis B following liver transplantation, and discusses multiple strategies to prevent hepatitis B recurrence. Lamivudine in combination with low-dose hepatitis B immuno-globulin currently is the most effective therapy to prevent recurrent hepatitis B virus allograft infection. It is emphasized that effective prophylaxis approaches against hepatitis B virus recurrence should be adopted before, during, and after operation. Long-term and even life-long antiviral therapy is important for a better outcome.
